MBX Biosciences, Inc.: shareholders and insiders

MBXNASDAQHealthcare · Pharmaceutical Preparations

Price

$53.42

November 18, 2026Market cap $2.5B

What Ploutos Investor adds for MBX Biosciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 19, 2025 to Nov 12, 2026, from their own Form 4 filings.

13 Form 4s

Bought on the market

$525.6K

1 person

Sold on the market

$3.0M

3 people

From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan89%
  • The rest11%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $525.6K by 1 person·sold $3.0M by 3 people

  • 2025: no buys, no sales
  • 2026: bought $525.6K by 1 person, sold $3.0M by 3 people
  • Nov 10, 2026Steven L. HoerterChairman, President and CEO
    Kind
  • Nov 4, 2026Salomon AzoulayChief Medical Officer
    Kind
  • Aug 4, 2026Salomon AzoulayChief Medical Officer
    Kind
  • Aug 3, 2026John W SmitherChief Financial Officer
    Kind
  • Aug 3, 2026Steven L. HoerterPresident and CEO
    Kind
  • May 8, 2026Salomon AzoulayChief Medical Officer
    Kind10b5-1
  • May 8, 2026Salomon AzoulayChief Medical Officer
    Kind10b5-1
  • May 6, 2026P. Kent HawrylukPresident & CEO
    Kind
  • May 6, 2026Salomon AzoulayChief Medical Officer
    Kind
  • Mar 13, 2026P. Kent HawrylukPresident & CEO
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 5, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by MBX's officers and directors from 2024 up to November 18, 2025, 2 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

7 Holders over 5%3 On a 13DNov 5, 2026 Latest filing
  • FMRwith 1 more person
    Share of class15.0%
  • Frazier Life Sciences Public Fund, L.P.with 7 more persons
    Share of class11.7%
  • Wellington Management Group LLPwith 3 more persons
    Share of class10.5%
  • New Enterprise Associates 17, L.P.with 11 more persons
    Share of class8.10%
  • Orbimed Advisorswith 2 more persons
    Share of class6.40%
  • BlackRock, Inc.
    Share of class5.50%
  • Paradigm BioCapital Advisors LPwith 3 more persons
    Share of class5.20%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • Frazier Life Sciences Public Fund, L.P.11.7%From the filing of Aug 10, 2026

    Item 4 is hereby amended to remove references to "FLSPOF" and the "FLSPOF Shares" from the first paragraph.

    From the filing of Aug 10, 2026
  • New Enterprise Associates 17, L.P.8.1%From the filing of Nov 10, 2025

    NEA 17 acquired the NEA 17 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 17 and the other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material…

    From the filing of Nov 10, 2025
  • Orbimed Advisors6.4%From the filing of Aug 10, 2026

    The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the…

    From the filing of Aug 10, 2026
Fell to 5% or less (4)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Deep Track Capital, LP3.64%Aug 14, 202613G/A
  • P. Kent Hawryluk4.30%Nov 14, 202513G/A
  • Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.4.50%Nov 12, 202513G/A
  • Norwest Venture Partners XVI, LP13D4.80%Sep 30, 202513D/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Millennium Mgmt (Englander)
    In the quarter
  • Citadel Advisors (Griffin)
    In the quarter
  • D.E. Shaw
    In the quarter-30%
  • AQR Capital
    In the quarter-0.5%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 9.31% of its shares outstanding were held short, -1.0% since the report before.

Shares held short
4.42M
9.31%
Since the report before4.47M on Sep 30, 2026
-1.0%
7.5
592.7K
More days to cover thanof 4,578 US-listed companies with enough volume
81%
Report date
Oct 15, 2026
  • Sep 30, 2024: Shares held short 363.7K
  • Oct 15, 2024: Shares held short 311.8K
  • Oct 31, 2024: Shares held short 350.7K
  • Nov 15, 2024: Shares held short 345.3K
  • Nov 29, 2024: Shares held short 485.2K
  • Dec 13, 2024: Shares held short 510.4K
  • Dec 31, 2024: Shares held short 1.67M
  • Jan 15, 2025: Shares held short 2.03M
  • Jan 31, 2025: Shares held short 2.80M
  • Feb 14, 2025: Shares held short 3.68M
  • Feb 28, 2025: Shares held short 4.11M
  • Mar 14, 2025: Shares held short 4.57M
  • Mar 31, 2025: Shares held short 5.08M
  • Apr 15, 2025: Shares held short 5.36M
  • Apr 30, 2025: Shares held short 5.38M
  • May 15, 2025: Shares held short 5.29M
  • May 30, 2025: Shares held short 4.75M
  • Jun 13, 2025: Shares held short 4.65M
  • Jun 30, 2025: Shares held short 4.97M
  • Jul 15, 2025: Shares held short 4.78M
  • Jul 31, 2025: Shares held short 5.34M
  • Aug 15, 2025: Shares held short 4.07M
  • Aug 29, 2025: Shares held short 3.84M
  • Sep 15, 2025: Shares held short 4.23M
  • Sep 30, 2025: Shares held short 3.90M
  • Oct 15, 2025: Shares held short 3.91M
  • Oct 31, 2025: Shares held short 4.58M
  • Nov 14, 2025: Shares held short 4.63M
  • Nov 28, 2025: Shares held short 4.10M
  • Dec 15, 2025: Shares held short 3.61M
  • Dec 31, 2025: Shares held short 3.84M
  • Jan 15, 2026: Shares held short 2.31M
  • Jan 30, 2026: Shares held short 1.97M
  • Feb 13, 2026: Shares held short 2.20M
  • Feb 27, 2026: Shares held short 2.40M
  • Mar 13, 2026: Shares held short 2.98M
  • Mar 31, 2026: Shares held short 3.59M
  • Apr 15, 2026: Shares held short 3.79M
  • Apr 30, 2026: Shares held short 4.03M
  • May 15, 2026: Shares held short 4.28M
  • May 29, 2026: Shares held short 4.81M
  • Jun 15, 2026: Shares held short 5.71M
  • Jun 30, 2026: Shares held short 5.90M
  • Jul 15, 2026: Shares held short 5.78M
  • Jul 31, 2026: Shares held short 5.19M
  • Aug 14, 2026: Shares held short 4.95M
  • Aug 31, 2026: Shares held short 4.16M
  • Sep 15, 2026: Shares held short 4.13M
  • Sep 30, 2026: Shares held short 4.47M
  • Oct 15, 2026: Shares held short 4.42M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading50.5% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 50.5% of the shares in the reported trades were short sales, against 50.5% in the 14 before.

Last 14 sessionsOct 30, 2026 – Nov 18, 2026
50.5%
The 14 beforeOct 12, 2026 – Oct 29, 2026
50.5%
Change
+0.0 pts
Short sales a dayon average, of 209.1K shares
105.6K
More than atof 3,656 US-listed companies, same days
51%
Median of alleight in ten from 34.4% to 63.7%
50.3%
  • Oct 12, 2026: Short sales 61.2%
  • Oct 13, 2026: Short sales 46.8%
  • Oct 14, 2026: Short sales 36.7%
  • Oct 15, 2026: Short sales 65.8%
  • Oct 16, 2026: Short sales 77.6%
  • Oct 19, 2026: Short sales 82.9%
  • Oct 20, 2026: Short sales 22.4%
  • Oct 21, 2026: Short sales 84.7%
  • Oct 22, 2026: Short sales 38.9%
  • Oct 23, 2026: Short sales 48.4%
  • Oct 26, 2026: Short sales 44.1%
  • Oct 27, 2026: Short sales 35.9%
  • Oct 28, 2026: Short sales 81.9%
  • Oct 29, 2026: Short sales 66.4%
  • Oct 30, 2026: Short sales 65.6%
  • Nov 2, 2026: Short sales 81.1%
  • Nov 3, 2026: Short sales 63.6%
  • Nov 4, 2026: Short sales 50.6%
  • Nov 5, 2026: Short sales 56.6%
  • Nov 6, 2026: Short sales 30.9%
  • Nov 9, 2026: Short sales 29.3%
  • Nov 10, 2026: Short sales 27.2%
  • Nov 11, 2026: Short sales 56.8%
  • Nov 12, 2026: Short sales 73.9%
  • Nov 13, 2026: Short sales 80.4%
  • Nov 16, 2026: Short sales 54.6%
  • Nov 17, 2026: Short sales 68.3%
  • Nov 18, 2026: Short sales 59.1%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

58.64M Insiders' shares123.43% Of the company
  • Fhmls X, L.p.TenPercentOwner
    Directly4.55M
  • Patrick J HeronDirector,TenPercentOwner
    Directly–
  • NEA Partners 17, L.P.TenPercentOwner
    Directly3.61M
  • Scott D SandellTenPercentOwner
    Directly–
  • Rick YangTenPercentOwner
    Directly–
  • Paul Edward WalkerTenPercentOwner
    Directly–
  • Mohamad MakhzoumiTenPercentOwner
    Directly–
  • Anthony A. Florence Jr.TenPercentOwner
    Directly–
  • Carmen ChangTenPercentOwner
    Directly–
  • Ali BehbahaniTenPercentOwner
    Directly–
  • Forest BaskettTenPercentOwner
    Directly–
  • Edward T MathersDirector,TenPercentOwner
    Directly–
  • OrbiMed Genesis GP LLCDirector,TenPercentOwner
    Directly–
  • Tiba AynechiDirector
    Directly–
  • P. Kent HawrylukPresident & CEO
    Directly727.7K
  • Carl L GordonDirector,TenPercentOwner
    Directly–
  • Orbimed Advisors LlcDirector,TenPercentOwner
    Directly–
  • Steven L. HoerterDirector
    Directly78.0K
  • John W SmitherChief Financial Officer
    Directly28.0K
  • Ora H. PescovitzDirector
    Directly24.3K
  • Salomon AzoulayChief Medical Officer
    Directly14.0K

A lower bound: it counts only the 21 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

18 ETFs holding it0.38% The largest weight (IWC)
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.38%
  • IHEiShares U.S. Pharmaceuticals ETF
    Weight in the fund0.34%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.13%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.12%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.10%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.06%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.05%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.03%
  • DFASDimensional U.S. Small Cap ETF
    Weight in the fund0.03%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.02%

18 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

173 Managers, Q2 2026$3.1B Value of their positions
  • Q3 2025: Managers 118
  • Q4 2025: Managers 138
  • Q1 2026: Managers 157
  • Q2 2026: Managers 173

Institutional investors by quarter

The fund managers holding MBX, quarter by quarter, from Q3 2024 to Q2 2025, 4 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 8 quarters.

Q2 2026: 173 managers held 55.48M shares, worth $3.1B. During the quarter 39 opened a position, 23 closed one, 60 added and 47 trimmed.

The largest holders, Q2 2026

  • Frazier Life Sciences Management
    In the quarter
  • FMR
    In the quarter+81%
  • Wellington Management Group
    In the quarter+56%
  • NEA Management
    In the quarter
  • Orbimed Advisors
    In the quarter-5.7%
  • BlackRock
    In the quarter+13%
  • Paradigm Biocapital Advisors
    In the quarter
  • Nvp Associates
    In the quarter
  • Deep Track Capital
    In the quarter-37%
  • Polar Capital Holdings
    In the quarter-0.8%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do MBX Biosciences's filings show?

Who buys and sells is one part of MBX Biosciences's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about MBX's shareholders

Didn't find what you were looking for?

Ask us
Have MBX's insiders bought or sold?

From Jun 5, 2026 to Nov 12, 2026 MBX Biosciences's insiders bought 0 and sold $312.7K of shares on the market. 0% of the sales were under set 10b5-1 plans.

Which well-known managers hold MBX?

4 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $7.5M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.